These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 28128058)

  • 41. Lipoprotein(a): more interesting than ever after 50 years.
    Dubé JB; Boffa MB; Hegele RA; Koschinsky ML
    Curr Opin Lipidol; 2012 Apr; 23(2):133-40. PubMed ID: 22327610
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Role of Antisense Therapies Targeting Lipoprotein(a).
    Plakogiannis R; Sorbera M; Fischetti B; Chen M
    J Cardiovasc Pharmacol; 2021 Jul; 78(1):e5-e11. PubMed ID: 34232223
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Practical management of dyslipidemia with elevated lipoprotein(a).
    Riche DM; East HE; Priest HM
    J Am Pharm Assoc (2003); 2008; 48(6):803-7. PubMed ID: 19019811
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study.
    Tsimikas S; Viney NJ; Hughes SG; Singleton W; Graham MJ; Baker BF; Burkey JL; Yang Q; Marcovina SM; Geary RS; Crooke RM; Witztum JL
    Lancet; 2015 Oct; 386(10002):1472-83. PubMed ID: 26210642
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of the effects of fibrates versus statins on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of head-to-head randomized controlled trials.
    Sahebkar A; Simental-Mendía LE; Watts GF; Serban MC; Banach M;
    BMC Med; 2017 Feb; 15(1):22. PubMed ID: 28153024
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical Trial Design for Lipoprotein(a)-Lowering Therapies: JACC Focus Seminar 2/3.
    Malick WA; Goonewardena SN; Koenig W; Rosenson RS
    J Am Coll Cardiol; 2023 Apr; 81(16):1633-1645. PubMed ID: 37076218
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Emerging therapeutic agents to lower lipoprotein (a) levels.
    Kolski B; Tsimikas S
    Curr Opin Lipidol; 2012 Dec; 23(6):560-8. PubMed ID: 23041907
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lp(a) and cardiovascular risk: Investigating the hidden side of the moon.
    Bucci M; Tana C; Giamberardino MA; Cipollone F
    Nutr Metab Cardiovasc Dis; 2016 Nov; 26(11):980-986. PubMed ID: 27514608
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Current therapies for lowering lipoprotein (a).
    van Capelleveen JC; van der Valk FM; Stroes ES
    J Lipid Res; 2016 Sep; 57(9):1612-8. PubMed ID: 26637277
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.
    Thomas GS; Cromwell WC; Ali S; Chin W; Flaim JD; Davidson M
    J Am Coll Cardiol; 2013 Dec; 62(23):2178-84. PubMed ID: 24013058
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lipoprotein(a) and Atherosclerotic Cardiovascular Disease, the Impact of Available Lipid-Lowering Medications on Lipoprotein(a): An Update on New Therapies.
    Tsushima T; Tsushima Y; Sullivan C; Hatipoglu B
    Endocr Pract; 2023 Jun; 29(6):491-497. PubMed ID: 36563785
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lipoprotein(a): cardiovascular risk and emerging therapies.
    Fujino M; Nicholls SJ
    Expert Rev Cardiovasc Ther; 2023 Apr; 21(4):259-268. PubMed ID: 37010028
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lipoprotein (a): When to Measure and How to Treat?
    Rhainds D; Brodeur MR; Tardif JC
    Curr Atheroscler Rep; 2021 Jul; 23(9):51. PubMed ID: 34235598
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Potent lipoprotein(a) lowering following apolipoprotein(a) antisense treatment reduces the pro-inflammatory activation of circulating monocytes in patients with elevated lipoprotein(a).
    Stiekema LCA; Prange KHM; Hoogeveen RM; Verweij SL; Kroon J; Schnitzler JG; Dzobo KE; Cupido AJ; Tsimikas S; Stroes ESG; de Winther MPJ; Bahjat M
    Eur Heart J; 2020 Jun; 41(24):2262-2271. PubMed ID: 32268367
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Considerations for routinely testing for high Lp(a).
    Nurmohamed NS; Moriarty PM; Stroes ESG
    Curr Opin Lipidol; 2022 Jun; 33(3):213-218. PubMed ID: 35695619
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lipoprotein(a) hyperlipidemia as cardiovascular risk factor: pathophysiological aspects.
    Schmitz G; Orsó E
    Clin Res Cardiol Suppl; 2015 Apr; 10(Suppl 1):21-5. PubMed ID: 25708587
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The role of antisense oligonucleotide therapy against apolipoprotein-CIII in hypertriglyceridemia.
    Gouni-Berthold I
    Atheroscler Suppl; 2017 Nov; 30():19-27. PubMed ID: 29096837
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lipoprotein(a): novel target and emergence of novel therapies to lower cardiovascular disease risk.
    Tsimikas S
    Curr Opin Endocrinol Diabetes Obes; 2016 Apr; 23(2):157-64. PubMed ID: 26825471
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [New data about lipoprotein(a): a curious molecule or a causal cardiovascular risk factor?].
    de Brouckère V; Liénart F; Ducobu J
    Rev Med Brux; 2010; 31(3):171-6. PubMed ID: 20687444
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacotherapy for children with elevated levels of lipoprotein(a): future directions.
    de Boer LM; Wiegman A; Swerdlow DI; Kastelein JJP; Hutten BA
    Expert Opin Pharmacother; 2022 Oct; 23(14):1601-1615. PubMed ID: 36047306
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.